Research Topics
| Craig T JordanSummaryAffiliation: University of Rochester Country: USA Publications
| Collaborators
|
Detail Information
Publications
Targeting the most critical cells: approaching leukemia therapy as a problem in stem cell biologyCraig T Jordan
James P Wilmot Cancer Center, University of Rochester, Rochester, NY 14642, USA
Nat Clin Pract Oncol 2:224-5. 2005- The potential of targeting malignant stem cells as a treatment for leukemiaCraig T Jordan
University of Rochester School of Medicine, 601 Elmwood Ave, Box 703 Rochester, NY 14642, USA
Future Oncol 1:205-7. 2005..This perspective article summarizes recent findings in the leukemia stem cell field and discusses new directions for therapy... - Cancer stem cellsCraig T Jordan
James P. Wilmot Cancer Center, University of Rochester School of Medicine, Rochester, NY 14642, USA
N Engl J Med 355:1253-61. 2006 - Searching for leukemia stem cells--not yet the end of the road?Craig T Jordan
James P Wilmot Cancer Center, University of Rochester School of Medicine, Rochester, New York 14642, USA
Cancer Cell 10:253-4. 2006..Biological features of leukemia stem cells in this system challenge previous thinking in several ways and suggest an unexpected degree of heterogeneity among stem cells in various forms of leukemia... - Group v secretory phospholipase A2 promotes atherosclerosis: evidence from genetically altered miceMeredith A Bostrom
Graduate Center for Nutritional Sciences, University of Kentucky, Lexington, KY, USA
Arterioscler Thromb Vasc Biol 27:600-6. 2007..However, there is no direct evidence that this enzyme promotes atherogenic processes in vivo... 
The leukemic stem cellCraig T Jordan
James P Wilmot Cancer Center, University of Rochester School of Medicine, 601 Elmwood Ave, Box 703, Rochester, NY 14642, USA
Best Pract Res Clin Haematol 20:13-8. 2007..This article summarizes recent findings in the leukemic stem cell field and discusses new directions for therapy...- Leukemia stem cells in a genetically defined murine model of blast-crisis CMLSarah J Neering
James P Wilmot Cancer Center, University of Rochester Medical Center, NY 14642, USA
Blood 110:2578-85. 2007..Taken together, the system provides a powerful means by which the in vivo behavior of LSCs versus HSCs can be characterized and candidate treatment regimens can be optimized for maximal specificity toward primitive leukemia cells... - Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8)Monica L Guzman
James P Wilmot Cancer Center, University of Rochester, NY 14642, USA
Blood 110:4436-44. 2007..We conclude that TDZD-8 uses a unique and previously unknown mechanism to rapidly target leukemia cells, including malignant stem and progenitor populations... - An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cellsMonica L Guzman
James P Wilmot Cancer Center, University of Rochester, NY 14642, USA
Blood 110:4427-35. 2007..Therefore, based on the collective preclinical data, we propose that the novel compound DMAPT has the potential to target human LSCs in vivo... - Protein kinase C-associated kinase is required for NF-kappaB signaling and survival in diffuse large B-cell lymphoma cellsSang Woo Kim
Department of Biomedical Genetics, University of Rochester Medical Center, Rochester, NY 14642, USA
Blood 111:1644-53. 2008..Together, these results indicate that PKK plays a pivotal role in the survival of human DLBCL cells and represents a potential target for DLBCL therapy... - Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression dataDuane C Hassane
James P Wilmot Cancer Center, University of Rochester School of Medicine and Dentistry, NY, USA
Blood 111:5654-62. 2008..These findings suggest the use of multicenter collections of high-throughput data to facilitate discovery of leukemia drugs and drug targets... - Identification of OCT6 as a novel organic cation transporter preferentially expressed in hematopoietic cells and leukemiasShimei Gong
Department of Pediatrics, University of Kentucky, Lexington, KY 40536, USA
Exp Hematol 30:1162-9. 2002..We sought to identify OCT genes preferentially expressed in hematopoietic cells... - Feverfew: weeding out the root of leukaemiaMonica L Guzman
Expert Opin Biol Ther 5:1147-52. 2005..Thus, this naturally occurring agent may provide new avenues of investigation for the treatment of leukaemia. In this article, characteristics of parthenolide are reviewed... - The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cellsMonica L Guzman
University of Rochester School of Medicine, 601 Elmwood Ave, Box 703, Rochester, NY 14642, USA
Blood 105:4163-9. 2005..On the basis of these findings, we propose that the activity of PTL triggers LSC-specific apoptosis and as such represents a potentially important new class of drugs for LSC-targeted therapy... - Considerations for targeting malignant stem cells in leukemiaMonica L Guzman
Blood and Marrow Transplant Program, Markey Cancer Center, Division of Hematology/Oncology, University of Kentucky Medical Center, Lexington, Kentucky, USA
Cancer Control 11:97-104. 2004..A better understanding of LSC cell and molecular biology will allow the design of more effective therapies... - The hematopoietic stem cell in myelodysplasiaJane L Liesveld
Leukemia Blood and Marrow Transplant Program, Rochester, NY, USA
Stem Cells 22:590-9. 2004.... - Mechanisms controlling pathogenesis and survival of leukemic stem cellsCraig T Jordan
Department of Medicine, University of Rochester Medical Center, 601 Elmwood Avenue, Box 703, NY 14642, USA
Oncogene 23:7178-87. 2004..In this review, we discuss emerging concepts in the field and describe how various molecular and cellular characteristics of leukemia cells might be exploited as a means to preferentially ablate malignant stem cells... - A new approach to treatment of acute myelogenous leukemia using targeted therapy in combination with standard chemotherapyCraig T Jordan
Leuk Res 28:1121-2. 2004 - Cancer stem cell biology: from leukemia to solid tumorsCraig T Jordan
Division of Hematology Oncology, University of Rochester School of Medicine, 601 Elmwood Avenue, Box 703, Rochester, New York 14642, USA
Curr Opin Cell Biol 16:708-12. 2004..Hence, a detailed understanding of stem cells and how they mediate tumor pathogenesis will be critical in developing more effective cancer therapies... - Preferential induction of apoptosis for primary human leukemic stem cellsMonica L Guzman
Blood and Marrow Transplant Program, Markey Cancer Center, Division of HematologyOncology, University of Kentucky Medical Center, Lexington, KY 40536-0093 USA
Proc Natl Acad Sci U S A 99:16220-5. 2002..Further, the data begin to elucidate the molecular mechanisms that underlie LSC-specific apoptosis and suggest new directions for AML therapy... - Eukaryotic translation initiation factor 4E activity is modulated by HOXA9 at multiple levelsIvan Topisirovic
Institute for Research in Immunovirology and Cancer, University of Montreal, Montreal, Quebec H3T 1J4, Canada
Mol Cell Biol 25:1100-12. 2005.... - Human cytomegalovirus gene expression during infection of primary hematopoietic progenitor cells: a model for latencyFelicia D Goodrum
Department of Molecular Biology, Princeton University, Princeton, NJ 80544, USA
Proc Natl Acad Sci U S A 99:16255-60. 2002..Some of these expressed viral genes may function in latency and are targets for further analysis. Altered gene expression in hematopoietic progenitors may be indicative of the nature and outcome of HCMV infection... 
The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic targetSaman Hewamana
Department of Haematology, School of Medicine, Cardiff University, Cardiff, United Kingdom
Blood 111:4681-9. 2008..001, r(2) = 0.3), implicating Rel A in fludarabine resistance. Taken together, these data indicate that Rel A represents an excellent therapeutic target for this incurable disease...- Aberrant eukaryotic translation initiation factor 4E-dependent mRNA transport impedes hematopoietic differentiation and contributes to leukemogenesisIvan Topisirovic
Structural Biology Program, Department of Physiology and Biophysics, Mount Sinai School of Medicine, New York University, One Gustave Levy Place, New York, NY 10029, USA
Mol Cell Biol 23:8992-9002. 2003..Thus, our findings indicate that this nuclear function of eIF4E can contribute to leukemogenesis by promoting growth and by impeding differentiation... - Differential outcomes of human cytomegalovirus infection in primitive hematopoietic cell subpopulationsFelicia Goodrum
Department of Molecular Biology, Princeton University, Princeton, NJ 08544, USA
Blood 104:687-95. 2004.... - Parathyroid hormone stimulates expression of the Notch ligand Jagged1 in osteoblastic cellsJonathan M Weber
Endocrine Division, Department of Medicine, University of Rochester School of Medicine, 601 Elmwood Avenue Box 693 Rochester, NY 14642, USA
Bone 39:485-93. 2006.... - High-risk acute lymphoblastic leukemia cells with bcr-abl and INK4A/ARF mutations retain susceptibility to alloreactive T cellsFaith M Young
Department of Medicine, University of Rochester, Rochester, New York, USA
Biol Blood Marrow Transplant 14:622-30. 2008..Thus, ALLs with INK4A/ARF or bcr/abl mutations are not intrinsically resistant to allogeneic T cell responses, suggesting that active immunotherapies against mHA have the potential to control such acute lymphoblastic leukemias...